Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Raymond James Boosts Boston Scientific (NYSE:BSX) Price Target to $122.00
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective lifted by equities research analysts at Raymond James from $119.00 to $122.00 in a report released on Thursday,Benzinga reports.
Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher.
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus forecast.
J.P. Morgan Remains a Buy on Boston Scientific (BSX)
In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Boston Scientific (BSX – Research Report), with a
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. All participants will be listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Jon Monson,
Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
Boston Scientific remains bullish despite tariffs, with sales buoyed by Minnesota tech
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Boston Scientific (NYSE:BSX) Given New $115.00 Price Target at Stifel Nicolaus
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Boston Scientific sees higher-than-expected 2025 profit on strong demand
The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...
FierceBiotech4d
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...
Scientific American2d
Stories by Priyanka Dayal McCluskey — Boston Globe
Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific ...
Boston Scientific targets 12%-14% EPS growth for 2025 with strong FARAPULSE and WATCHMAN momentum
Q4 2024 Management View CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in ...